Psoriatic arthritis: Epidemiology, clinical features, course, and outcome

Annals of the Rheumatic Diseases

Volumn 64, Issue SUPPL. 2, 2005, Pages

  Gladman, D D ^a,i   Antoni, C ^b   Mease, P ^c,d,e   Clegg, D O ^f   Nash, O ^g,h  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Rheumatology Associates   (United States)

^d Swedish Hospital Medical Center   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g NAMBOUR GENERAL HOSPITAL   (Australia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

ⁱ TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CONFERENCE PAPER; DISEASE COURSE; HEALTH STATUS; HUMAN; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE;

ADULT; ARTHRITIS, PSORIATIC; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; QUALITY OF LIFE;

EID: 14244260176     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.032482     Document Type: Conference Paper

References (53)

1. Wright V, Moll JMH. Psoriatic arthritis. In: Wright V, Moll JMH, eds. Seronegative polyarthritis. Amsterdam: North Holland Publishing Co, 1976:169-223.
2. Cats A. Psoriasis and arthritis. Cutis 1990;46:323-9.
3. O'Neill T, Silman AJ. Psoriatic arthritis. Historical background and epidemiology. Baillieres Clin Rheumatol 1994;8:245-61.
4. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64(suppl II):ii37-9.
5. Gladman DD. Psoriatic arthritis. Baillieres Clin Rheumatol 1995;9:319-29.
6. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005;64(suppl II):ii3-8.
7. Bruce IN. Psoriatic arthritis: clinical features. In: Hochberg MC, Silman JS, Smolen ME, Weinblatt M, Weisman M, eds. Rheumatology, 3rd edn. Philadelphia: Mosby, 2003:1241-52.
8. Savolainen E, Kaipiainen-Seppanen O, Kroger L, Luosujarvi R. Total incidence and distribution or inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 2003;30:2460-8.
9. Soderlin MK, Barjesson O, Kautiainen H, Skogh T, Leirisalo-Repa M. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002;61:911-15.
10. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7.
11. Brockbank JE, Schentog C, Rosen C, Gladman DD. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medical clinic attendees [abstract]. Arthritis Rheum 2001;44(suppl 9):S94.
12. Gladman DD, Rahman P. Psoriatic arthritis. In: Ruddy S, Harris ED, Sledge CB, Budd RC, Sarjent JS, eds. In: Kelly's Textbook of Rheumatology, 6th edn. Philadelphia: WB Saunders Co, 2001:1071-9.
13. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003;42:778-83.
14. Roberts ME, Wright V, Hill AG, Mehra AC. Psoriatic arthritis. Follow-up study. Ann Rheum Dis 1976;35:206-12.
15. Kammer GM, Soter NA, Gibson DJ, Schur PH. Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979;9:75-97.
16. Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984;23:246-50.
17. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)-an analysis of 220 patients. Q J Med 1987;62:127-41.
18. Helliwell P, Marchesoni A, Peters M, Barker M, Wright V. A re-evaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 1991;30:339-45.
19. Torre-Alanso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study. Br J Rheumatol 1991;30:245-50.
20. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133-8.
21. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994;33:834-9.
22. Trabace S, Cappellacci S, Ciccarone P, Liaskos S, Polito R, Zorzin L. Psoriatic arthritis: a clinical, radiological and genetic study of 58 Italian patients. Acta Derm Venereol Suppl (Stockh) 1994;186:69-70.
23. Marsal S, Armadans-Gil L, Martinez M, Gallardo D, Ribera A, Lience E. Clinical, radiographic and HLA associations as markers for differenf patterns of psoriatic arthritis. Rheumatology (Oxford) 1999;38:332-7.
24. Gladman DD. Clinical aspects of the spondyloarthropathies. Am J Med Sci 1998;316:234-8.
25. Ory PA. Radiography in the assessment of musculoskeletal conditions. Best Pract Res Clin Rheumatol 2003;17:495-512.
26. Olivieri I, Barozzi L, Pierro A, De Matteis M, Padula A, Pavlica P. Toe dactylitis in patients with spondyloarthropathy: assessment by magnetic resonance imaging. J Rheumatol 1997;24:926-30.
27. Gladman DD, Anhorn KA, Schachter RK, Mervart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986;13:586-92.
28. Eastmond CJ, Wright V. The nail dystrophy of psoriatic arthritis. Ann Rheum Dis 1979;38:2:226-8.
29. Clegg DO, Redo DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
30. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
31. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
32. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progession. Arthritis Rheum 2004;50:2264-72.
33. Antoni C, Kavanaugh A, Kirkham B, Burmester Q, Weism M, Keystone E, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2002;46:S381.
34. Kavanaugh A, Krueger GG, DeVlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves arthritis and psoriasis in patients with active polyarticular psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis 2004;63(suppl 1):402.
35. Gladman DD. The natural history of psoriatic arthritis. In: Wright V, Helliwell PS, eds. Psoriatic arthritis in Baillière's Clinical Rheumatology. International Practice and Research. London: Baillière Tindall, 1994:379-94.
36. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience Rheumatology (Oxford) 2003;42:1460-8.
37. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995;22:675-9.
38. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003;62:68-70.
39. Gladman DD, Farewell VT, Kopciuk K, Cook RJ. HLA antigens and progression in psoriatic arthritis. J Rheumatol 1998;25:730-3.
40. Gladman DD, Farewell VT. Progression in psoriatic arthritis: Role of time varying clinical indicators. J Rheumatol 1999;26:2409-13.
41. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72.
42. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: Results from a single center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10.
43. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50.
44. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001;28:1041-4.
45. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-0.
46. Gladman DD, Hing EN, Schentag CT, Cook RJ. Remission in psoriatic arthritis. J Rheumatol 2001;28:1045-8.
47. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997;24:511-17.
48. Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002;82:108-13.
49. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001;45:151-8.
50. Husted JA, Gladman DD, Cook RJ, Farewell VT. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998;25:2146-55.
51. Husted J, Gladman DD, Long J, Farewell VT. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995;13:439-44.
52. McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63:162-9.
53. Kammer GM, Soter NA, Gibson Blackmore M, Gladman DD, Husted J, Long J, et al. Measuring health status in psoriatic arthritis: The Health Assessment Questionnaire and its modification. J Rheumatol 1995;22:886-93.